$DCTH News

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath (DCTH) Q1 2026 Earnings Transcript

Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript

Delcath Systems Q1 Earnings Call Highlights

Delcath Systems (NASDAQ:DCTH) Surpasses Q1 Estimates, Guidance Points to Continued Growth

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems FY2026 Revenue expected to be more than $100.000M vs $104.070M Est

Delcath Systems Q1 EPS $(0.03) Beats $(0.10) Estimate, Sales $24.994M Beat $23.383M Estimate

How The Delcath Systems (DCTH) Story Is Shifting With Hepzato Milestones And 2026 Guidance

Delcath Systems to Host First Quarter 2026 Earnings Call

Implied Volatility Surging for Delcath Systems Stock Options

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Delcath Systems' CHEMOSAT M-PHP Recognized As Recommended Liver-Directed Therapy For Metastatic Uveal Melanoma In 2026 ESMO–EURACAN Guidelines

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results